Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 771 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease Sickle Cell Anemia Clear all
Completed Not applicable Interventional

Parent Educational Program for Children With Sickle Cell Disease

NCT00860782
View directory record Official record
Conditions
Hemoglobin SC Disease, Anemia, Sickle Cell
Interventions
Parent Educational Support
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
6 Years to 12 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 29, 2026, 6:44 AM EDT
Recruiting No phase listed Observational

Natural History of Sickle Cell Disease

NCT00081523
View directory record Official record
Conditions
Pain Crisis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Not applicable Interventional

The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT

NCT02729350
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Guided Relaxation video clip, Sickle Cell Disease Experience Discussion
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Phase 2 Interventional Results available

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

NCT00125788
View directory record Official record
Conditions
Sickle Cell Anemia, Thalassemia
Interventions
L-glutamine, Placebo
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Bellflower, California • Torrance, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 29, 2026, 6:44 AM EDT
Terminated Not applicable Interventional Results available

COVID-19 Testing in Underserved and Vulnerable Populations

NCT05315908
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases, COPD, Obesity, Sickle Cell Disease, Diabetes Mellitus, Type 2
Interventions
Community outreach method
Other
Lead sponsor
Jesse Nodora
Other
Eligibility
21 Years and older
Enrollment
9,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 29, 2026, 6:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease

NCT00451919
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 29, 2026, 6:44 AM EDT
Completed No phase listed Observational

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

NCT04349189
View directory record Official record
Conditions
Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State, Venous Thromboembolism
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 6:44 AM EDT
Completed No phase listed Observational

Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

NCT06662825
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
16 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 29, 2026, 6:44 AM EDT
Active, not recruiting No phase listed Observational

Stroke Prevention in Young Adults With Sickle Cell Anemia

NCT04808778
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic, Silent Stroke, Silent Cerebral Infarct, Stroke
Interventions
Hydroxyurea therapy per standard care
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years to 26 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sickle Cell Anemia WE CARE

NCT03716726
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
WE CARE SDoH Screening Survey, Family Resource Book, Standard of care
Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 29, 2026, 6:44 AM EDT
Terminated Phase 2 Interventional

Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions
HQK-1001, Placebo
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Mobile, Alabama • Oakland, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 29, 2026, 6:44 AM EDT
Active, not recruiting Phase 1 Interventional

A Blood Stem Cell Transplant for Sickle Cell Disease

NCT03249831
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Interventions
Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Phase 2 Interventional

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

NCT00067080
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

NCT00911495
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GMI-1070
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Oakland, California • Sacramento, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 29, 2026, 6:44 AM EDT
Not listed Phase 2 Interventional

Rifaximin to Modify the Disease Course in Sickle Cell Disease

NCT03719729
View directory record Official record
Conditions
Sickle Cell Disease, Antibiotics
Interventions
Rifaximin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

NCT02567695
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 29, 2026, 6:44 AM EDT
Completed No phase listed Observational

Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease

NCT02227472
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Evaluation of cognitive and pre-academic skills, Parent questionnaires
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
48 Months to 68 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 29, 2026, 6:44 AM EDT
Active, not recruiting Phase 2 Interventional

Reduced Intensity Transplantation for Severe Sickle Cell Disease

NCT04362293
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 6:44 AM EDT
Terminated Phase 4 Interventional Results available

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

NCT00115336
View directory record Official record
Conditions
Hematologic Diseases, Anemia, Sickle Cell
Interventions
Intravenous Ketorolac, Ibuprofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 29, 2026, 6:44 AM EDT
Completed Phase 4 Interventional Results available

Actigraphy Improvement With Voxelotor (ActIVe) Study

NCT04400487
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Farmington, Connecticut • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 29, 2026, 6:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)

NCT02990598
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 29, 2026, 6:44 AM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 29, 2026, 6:44 AM EDT
Completed No phase listed Observational

Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease

NCT00305175
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 29, 2026, 6:44 AM EDT
Terminated Phase 1 Interventional

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

NCT07431398
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Pociredir
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Riverdale, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 29, 2026, 6:44 AM EDT